Donald Patrick McDonnell
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of MedicineOverview
The research in our group is focused on the development and application of mechanism based approaches to identify novel therapeutics for use in the treatment and prevention of hormonally responsive cancers. Specifically we are interested in the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic targets in breast and prostate cancers and in defining how these receptors influence the pathogenesis of these diseases. These efforts have led to the discovery of several drugs that are currently being evaluated in the clinic as cancer therapeutics, and to the identification of potential biomarkers and predictors of response that can help to target the use of these new drugs. Most recently we have explored approaches to treat triple negative breast cancer and have identified an important pathway that links obesity/dyslipidemia and cancer risk.
Positions
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine in the School of Medicine
2002 School of Medicine
Professor of Pharmacology and Cancer Biology in the School of Medicine
2000 School of Medicine
Professor of Cell Biology in the School of Medicine
2022 School of Medicine
Professor in Medicine in the School of Medicine
2002 School of Medicine
Member of the Duke Cancer Institute in the School of Medicine
1994 School of Medicine
Education
Ph.D. 1988
1988 Baylor, College of Medicine
Publications, Grants & Awards
DCI Centers, Cancer Types & Labs
Offices & Contact
2138 MSRB3
Durham, NC
27710
Duke Box 3813
Durham, NC
27710